Form 4: Boxer Capital Management Sells 633,000 Shares of Tango Therapeutics

Boxer Capital Management, a significant shareholder in Tango Therapeutics, sold 633,000 shares of common stock at an average price of $6.87.

Summary

• Boxer Capital Management, LLC, along with Aaron I. Davis, filed a Form 4 detailing changes in beneficial ownership of Tango Therapeutics, Inc. (TNGX).
• On October 25, 2024, Boxer Capital Management sold 633,000 shares of common stock at a weighted average price of $6.87 per share.
• The sales were executed in multiple transactions with prices ranging from $6.85 to $6.87.
• Following the transaction, Boxer Capital Management directly owns 6,690,642 shares.
• Additionally, MVA Investors, LLC owns 108,793 shares, and BCTG Holdings, LLC owns 6,988,450 shares.
• Aaron I. Davis, as Managing Member of Boxer Capital Management and member of MVA Investors and BCTG Holdings, disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. A large shareholder selling a significant number of shares can create uncertainty, but it doesn't necessarily indicate a negative outlook for the company. The disclaimers of beneficial ownership by Davis add a layer of complexity.

Negatives

• Boxer Capital Management, a significant shareholder, reduced its stake in Tango Therapeutics by selling 633,000 shares.

Risks

• Continued selling pressure from major shareholders like Boxer Capital Management could negatively impact the stock price of Tango Therapeutics.

Industry Context

Form 4 filings are standard disclosures for significant shareholders and insiders, providing transparency into their trading activities. This sale by Boxer Capital Management could be interpreted in various ways by the market, depending on the overall sentiment and performance of Tango Therapeutics and the broader biotechnology sector.

Comparison to Industry Standards

• Form 4 filings are a standard practice across all publicly listed companies, including biotechnology firms like Tango Therapeutics.
• Similar transactions are routinely disclosed by major shareholders in companies like Amgen, Gilead Sciences, and Biogen, allowing investors to track insider sentiment and potential shifts in ownership.

Stakeholder Impact

• The sale of shares by Boxer Capital Management could potentially impact shareholder confidence and the stock price of Tango Therapeutics.
• The transaction does not appear to directly impact employees, customers, suppliers, or creditors.

Key Dates